Zhimin Shao - Concepedia

Author

Zhimin Shao

Fudan University Shanghai Cancer Center

Also Known As

Binghe Xu, Keda Yu, S. Zhimin, Shao Zhi-min, Shao Zhimin, Z M Shao, Z Shao, Z. Shao, Z.-M. Shao, Z.-m. Shao

144

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Fudan University Shanghai Cancer Center Shanghai Medical College of Fudan University Fudan University Harbin Medical University Sun Yat-sen University

About

Zhimin Shao is an author at Fudan University Shanghai Cancer Center specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	942
2	Health Sciences	2	2	41
3	Cell Biology	2	2	42
4	Engineering	1	1	26
5	Biochemistry	1	1	21

Zhimin Shao

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer Andrew Tutt, Judy E. Garber, Bella Kaufman, New England Journal of Medicine	2021	1.6K
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial Sara A. Hurvitz, Fabrice André, Zefei Jiang, The Lancet Oncology Breast OncologyOncologyPharmacologyClinical TrialsBreast Cancer	2015	300
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia Zhimin Shao, Da Pang, Hongjian Yang, JAMA Oncology	2019	184
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial Nadia Harbeck, Chiun‐Sheng Huang, Sara A. Hurvitz, The Lancet Oncology Breast OncologyPrevious Trastuzumab TreatmentMedicinePharmacologyClinical Trials	2016	150
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib Leiping Wang, Qunling Zhang, Jian Zhang, BMC Cancer	2011	145
Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer Jia Jin, Yu Gao, Jian Zhang, BMC Cancer	2018	114
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial Junjie Li, Ke‐Da Yu, Da Pang, Journal of Clinical Oncology	2020	103
Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer Xiu-Zhi Zhu, Li Chen, Binhao Huang, Journal of Experimental & Clinical Cancer Research	2021	84
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer Massimo Cristofanilli, Stephen Johnston, Alexey Manikhas, Breast Cancer Research and Treatment	2012	79
Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy Minhao Fan, Jian Zhang, Zhonghua Wang, Breast Cancer Research and Treatment HypertensionAdvanced Breast CancerAngiogenesisBreast OncologyMedicine	2013	74

Page 1